INTRODUCTION: Treatment with alemtuzumab is highly effective in relapsing-remitting multiple sclerosis; however, 30% of patients develop autoimmunity. Alemtuzumab (previously called Campath 1-H) induces a prolonged T-cell lymphopenia with memory cells dominating the reconstituting T-cell pool for at least 3 months. RESULTS: Here we show that B-cell recovery is rapid, returning to baseline by 3 months and rising to 165% of baseline by 12 months after treatment. Immature transitional 1 B cells are the predominant cell type 1 month after treatment. This coincides with a surge in serum B-cell activating factor (BAFF), which remains elevated by 33% for at least 12 months after alemtuzumab. BAFF is critical for transition to the mature naive B-cell phenotype, which dominates from 3 months after alemtuzumab. Differentiation to memory B cells is slow so there are radical and prolonged alterations to the B-cell pool after alemtuzumab.
INTRODUCTION: Treatment with alemtuzumab is highly effective in relapsing-remitting multiple sclerosis; however, 30% of patients develop autoimmunity. Alemtuzumab (previously called Campath 1-H) induces a prolonged T-cell lymphopenia with memory cells dominating the reconstituting T-cell pool for at least 3 months. RESULTS: Here we show that B-cell recovery is rapid, returning to baseline by 3 months and rising to 165% of baseline by 12 months after treatment. Immature transitional 1 B cells are the predominant cell type 1 month after treatment. This coincides with a surge in serum B-cell activating factor (BAFF), which remains elevated by 33% for at least 12 months after alemtuzumab. BAFF is critical for transition to the mature naive B-cell phenotype, which dominates from 3 months after alemtuzumab. Differentiation to memory B cells is slow so there are radical and prolonged alterations to the B-cell pool after alemtuzumab.
Authors: Kristen L Hoek; Pierre Antony; John Lowe; Nicholas Shinners; Bhaskarjyoti Sarmah; Susan R Wente; Demin Wang; Rachel M Gerstein; Wasif N Khan Journal: J Immunol Date: 2006-10-15 Impact factor: 5.422
Authors: J A Gross; J Johnston; S Mudri; R Enselman; S R Dillon; K Madden; W Xu; J Parrish-Novak; D Foster; C Lofton-Day; M Moore; A Littau; A Grossman; H Haugen; K Foley; H Blumberg; K Harrison; W Kindsvogel; C H Clegg Journal: Nature Date: 2000-04-27 Impact factor: 49.962
Authors: Joanna Groom; Susan L Kalled; Anne H Cutler; Carl Olson; Stephen A Woodcock; Pascal Schneider; Jurg Tschopp; Teresa G Cachero; Marcel Batten; Julie Wheway; Davide Mauri; Dana Cavill; Tom P Gordon; Charles R Mackay; Fabienne Mackay Journal: J Clin Invest Date: 2002-01 Impact factor: 14.808
Authors: William Stohl; Samy Metyas; Soon-Min Tan; Gurtej S Cheema; Bonifacia Oamar; Dong Xu; Viktor Roschke; Youmei Wu; Kevin P Baker; David M Hilbert Journal: Arthritis Rheum Date: 2003-12
Authors: Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon Journal: N Engl J Med Date: 2008-10-23 Impact factor: 91.245
Authors: Mark D Willis; Trevor P Pickersgill; Neil P Robertson; Richard W J Lee; Andrew D Dick; Ester Carreño Journal: Int Ophthalmol Date: 2016-10-11 Impact factor: 2.031